Aura Biosciences, Inc.
AURAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company carries a $653.3M market cap, placing it firmly in the small-cap category. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Market Cap
$653.3M
Beta
0.41
P/E (TTM)
—
P/E (Fwd)
-3.10
EPS (TTM)
$-1.70
EPS (Fwd)
$-2.03
ROE
-53.5%
ROA
-31.2%
Cash
$323.8M
Total Debt
$16.6M
Free CF
-$56.3M
52W Change
7.5%
Annual Financials
Cash vs Debt
Where AURA stands vs its 150-day and 200-day moving averages
As of the October 9, 2026 close, AURA finished 7.28% below its 150-day moving average ($7.01) and 2.11% below its 200-day moving average ($6.64). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AURA overbought or oversold?
At the October 9, 2026 close, AURA's RSI(14) was 51.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Aura Biosciences, Inc. holds $323.8M in cash against $16.6M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$56.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -53.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of 0.41 suggests AURA is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Aura Biosciences, Inc.'s trajectory.